The U.S. artemisinic acid market size was estimated at USD 236.6 million in 2024 and is projected to reach USD 367.7 million by 2033, growing at a CAGR of 5.0% from 2025 to 2033. The primary factors driving the U.S. artemisinic acid market include an increase in malaria cases connected to international travel, the rising global resistance to traditional antimalarials, government-supported stockpiling initiatives, and expanded research and development in semi-synthetic production methods.
The rise of Plasmodium falciparum strains resistant to traditional antimalarial drugs in Africa and Southeast Asia is prompting healthcare providers and policymakers to prioritize access to fast-acting artemisinin-based treatments. As resistance patterns evolve, U.S. institutions increase their reliance on advanced artemisinic formulations, driving imports, R&D investment, and stockpiling of effective therapies to ensure readiness against more virulent malaria forms.
Furthermore, biotechnology innovations such as engineered Saccharomyces cerevisiae (yeast)-have enabled more stable and scalable production of artemisinic acid. This reduces reliance on agricultural sources such as Artemisia annua, vulnerable to climate and yield variability. As pharmaceutical companies adopt these methods, the U.S. market benefits from enhanced production reliability and cost-efficiency, supporting broader distribution and emergency preparedness.
This product will be delivered within 2 business days.
The rise of Plasmodium falciparum strains resistant to traditional antimalarial drugs in Africa and Southeast Asia is prompting healthcare providers and policymakers to prioritize access to fast-acting artemisinin-based treatments. As resistance patterns evolve, U.S. institutions increase their reliance on advanced artemisinic formulations, driving imports, R&D investment, and stockpiling of effective therapies to ensure readiness against more virulent malaria forms.
Furthermore, biotechnology innovations such as engineered Saccharomyces cerevisiae (yeast)-have enabled more stable and scalable production of artemisinic acid. This reduces reliance on agricultural sources such as Artemisia annua, vulnerable to climate and yield variability. As pharmaceutical companies adopt these methods, the U.S. market benefits from enhanced production reliability and cost-efficiency, supporting broader distribution and emergency preparedness.
U.S. Artemisinic Acid Market Report Segmentation
This report forecasts revenue growth at U.S. artemisinic acid market and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. artemisinic acid market report based on product.Product Outlook (Revenue, USD Million, 2021-2033)
- Antimalarial Injections
- Antimalarial Tablets
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Report Deliverables
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Artemisinic Acid Market Variable Trends & Scope
Chapter 4. U.S. Artemisinic Acid Market: Product Estimates & Trend Analysis
Chapter 5. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this U.S. Artemisinic Acid market report include:- Sanofi
- KPC Pharmaceuticals, Inc.
- Guilin Pharmaceutical Co., Ltd
- Calyx Chemicals and Pharmaceuticals Ltd.
- Novartis Pharmaceuticals Corporation
- Ipca Laboratories Inc.
- Cipla USA Inc.
- SHINPOONG. Co, Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | October 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 236.6 Million |
| Forecasted Market Value ( USD | $ 367.7 Million |
| Compound Annual Growth Rate | 5.0% |
| Regions Covered | United States |
| No. of Companies Mentioned | 9 |
